Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a Miami‑based biotech company developing transformative therapies for emerging infectious diseases. It is advancing an Ebola antibody (Ebanga™) and a COVID‑19 antiviral (molnupiravir). It is focused, early‑stage, and driven by global public health needs.
Address: 3480 Main Highway, Miami, FL 33133
Phone: (786) 687-2495
-
Despite US Competition, Merck’s COVID-19 At-home Treatment Going Strong in Other Countries
While the experimental COVID-19 pill developed by Merck, the pharmaceutical giant with sizable operations in West Point, is being edged…
-
Merck’s Experimental COVID-19 Pill is Less Effective Than Predicted by Early Clinical Trials
The experimental COVID-19 pill developed by Merck, the pharmaceutical giant with sizable operations in West Point, and its partner Ridgeback…
-
Merck Drug One Step Closer to Becoming First At-Home COVID-19 Treatment
A COVID-19 pill created by Merck, the pharmaceutical giant with sizable operations in West Point, and Ridgeback Biotherapeutics performed well…
-
Merck, GlaxoSmithKline Report Progress on COVID-19 Drug Candidates
Merck and GlaxoSmithKline, both with significant operations in Montgomery County, reported progress on COVID-19 experimental medicines they are working on…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
